• Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema
  • Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases

ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the publication of a comprehensive review article in Clinical Reviews in Allergy & Immunology providing a state-of-the-art overview of the biology of bradykinin and the bradykinin B2 receptor (B2R), and summarizing the growing body of evidence supporting B2R antagonism as a therapeutic strategy for bradykinin-mediated diseases. Drawing on decades of scientific and clinical research, the article traces the evolution of bradykinin B2 receptor antagonism from foundational discoveries in kinin biology to a clinically validated therapeutic approach.